Oocyte-Secreted Factors Synergize With FSH to Promote Aromatase Expression in Primary Human Cumulus Cells

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2018 Dec 13

PMID 30541132

Citations 19

Authors

Elie Hobeika

Marah Armouti

Hamsini Kala

Michele A Fierro

Nicola J Winston

Bert Scoccia

Alberuni M Zamah

Carlos Stocco

Affiliations

Soon will be listed here.

Abstract

Context: The role of growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) on aromatase regulation is poorly understood in humans.

Objective: Determine GDF9 and BMP15 effects on FSH stimulation of estradiol production in primary human cumulus granulosa cells (GCs). We hypothesized that the combination of GDF9 and BMP15 potentiates FSH-induced aromatase expression.

Design: Primary human cumulus GCs in culture.

Setting: University infertility center.

Patients Or Other Participants: GCs of 60 women undergoing in vitro fertilization were collected.

Interventions: Cells were treated with GDF9 and/or BMP15 (GB) in the presence or absence of FSH, dibutyryl cAMP, or SMAD inhibitors.

Main Outcome Measures: Promoter activity, mRNA, protein, and estradiol levels were quantified.

Results: FSH and GB treatment increased CYP19A1 promoter activity, mRNA, and protein levels as well as estradiol when compared with cells treated with FSH only. GB treatment potentiated cAMP stimulation of aromatase and IGF2 stimulation by FSH. GB effects were inhibited by SMAD3 inhibitors and IGF1 receptor inhibitors. GB, but not FSH, stimulates SMAD3 phosphorylation.

Conclusion: The combination of GDF9 and BMP15 potently stimulates the effect of FSH and cAMP on CYP19a1 promoter activity and mRNA/protein levels. These effects translate into an increase in estradiol production. This potentiation seems to occur through activation of the SMAD2/3 and SMAD3 signaling pathway and involves, at least in part, the effect of the IGF system.

Citing Articles

Protective effect of luteinizing hormone on frozen-thawed ovarian follicles and granulosa cells.

Chen J, Yu B, Zhang S, Wang Z, Dai Y PLoS One. 2025; 20(1):e0317416.

PMID: 39808671 PMC: 11731763. DOI: 10.1371/journal.pone.0317416.

Unraveling the complexity of follicular fluid: insights into its composition, function, and clinical implications.

Pan Y, Pan C, Zhang C J Ovarian Res. 2024; 17(1):237.

PMID: 39593094 PMC: 11590415. DOI: 10.1186/s13048-024-01551-9.

Molecular crosstalk between insulin-like growth factors and follicle-stimulating hormone in the regulation of granulosa cell function.

Hayes E, Winston N, Stocco C Reprod Med Biol. 2024; 23(1):e12575.

PMID: 38571513 PMC: 10988955. DOI: 10.1002/rmb2.12575.

Single-Cell Transcriptome Analysis Reveals Development-Specific Networks at Distinct Synchronized Antral Follicle Sizes in Sheep Oocytes.

Song Y, Zhang N, Zhang Y, Wang J, Lv Q, Zhang J Int J Mol Sci. 2024; 25(2).

PMID: 38255985 PMC: 10815039. DOI: 10.3390/ijms25020910.

E2/ER signaling mediates the meiotic arrest of goat intrafollicular oocytes induced by follicle-stimulating hormone.

Lu S, Tang Y, Yao R, Xu R, Zhang H, Liu J J Anim Sci. 2023; 101.

PMID: 37925610 PMC: 10630185. DOI: 10.1093/jas/skad351.

References

Stocco C, Baumgarten S, Armouti M, Fierro M, Winston N, Scoccia B . Genome-wide interactions between FSH and insulin-like growth factors in the regulation of human granulosa cell differentiation. Hum Reprod. 2017; 32(4):905-914. PMC: 5400056. DOI: 10.1093/humrep/dex002. View

Moore R, Otsuka F, Shimasaki S . Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem. 2002; 278(1):304-10. DOI: 10.1074/jbc.M207362200. View

McNatty K, Juengel J, Reader K, Lun S, Myllymaa S, Lawrence S . Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function. Reproduction. 2005; 129(4):473-80. DOI: 10.1530/rep.1.0511. View

Garcia-Echeverria C, Pearson M, Marti A, Meyer T, Mestan J, Zimmermann J . In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004; 5(3):231-9. DOI: 10.1016/s1535-6108(04)00051-0. View

Brazert M, Pawelczyk L . Insulin-like growth factor-1 isoforms in human ovary. Preliminary report on the expression of the IGF-1 gene in PCOS patients and healthy controls. Ginekol Pol. 2016; 86(12):890-5. DOI: 10.17772/gp/60708. View

Kovanci E, Rohozinski J, Simpson J, Heard M, Bishop C, Carson S . Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril. 2006; 87(1):143-6. DOI: 10.1016/j.fertnstert.2006.05.079. View

Mottershead D, Ritter L, Gilchrist R . Signalling pathways mediating specific synergistic interactions between GDF9 and BMP15. Mol Hum Reprod. 2011; 18(3):121-8. PMC: 3292392. DOI: 10.1093/molehr/gar056. View

Crawford J, McNatty K . The ratio of growth differentiation factor 9: bone morphogenetic protein 15 mRNA expression is tightly co-regulated and differs between species over a wide range of ovulation rates. Mol Cell Endocrinol. 2011; 348(1):339-43. DOI: 10.1016/j.mce.2011.09.033. View

Rossetti R, Di Pasquale E, Marozzi A, Bione S, Toniolo D, Grammatico P . BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat. 2009; 30(5):804-10. PMC: 2677132. DOI: 10.1002/humu.20961. View

10.

Al-Musawi S, Walton K, Heath D, Simpson C, Harrison C . Species differences in the expression and activity of bone morphogenetic protein 15. Endocrinology. 2013; 154(2):888-99. DOI: 10.1210/en.2012-2015. View

11.

Monestier O, Servin B, Auclair S, Bourquard T, Poupon A, Pascal G . Evolutionary origin of bone morphogenetic protein 15 and growth and differentiation factor 9 and differential selective pressure between mono- and polyovulating species. Biol Reprod. 2014; 91(4):83. DOI: 10.1095/biolreprod.114.119735. View

12.

Winterhager E, Kidder G . Gap junction connexins in female reproductive organs: implications for women's reproductive health. Hum Reprod Update. 2015; 21(3):340-52. DOI: 10.1093/humupd/dmv007. View

13.

Petraglia F, Serour G, Chapron C . The changing prevalence of infertility. Int J Gynaecol Obstet. 2013; 123 Suppl 2:S4-8. DOI: 10.1016/j.ijgo.2013.09.005. View

14.

Ombelet W, Cooke I, Dyer S, Serour G, Devroey P . Infertility and the provision of infertility medical services in developing countries. Hum Reprod Update. 2008; 14(6):605-21. PMC: 2569858. DOI: 10.1093/humupd/dmn042. View

15.

Auclair S, Rossetti R, Meslin C, Monestier O, Di Pasquale E, Pascal G . Positive selection in bone morphogenetic protein 15 targets a natural mutation associated with primary ovarian insufficiency in human. PLoS One. 2013; 8(10):e78199. PMC: 3797742. DOI: 10.1371/journal.pone.0078199. View

16.

Hayashi M, Mcgee E, Min G, Klein C, Rose U, van Duin M . Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. Endocrinology. 1999; 140(3):1236-44. DOI: 10.1210/endo.140.3.6548. View

17.

Persani L, Rossetti R, Di Pasquale E, Cacciatore C, Fabre S . The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. Hum Reprod Update. 2014; 20(6):869-83. DOI: 10.1093/humupd/dmu036. View

18.

Heath D, Pitman J, McNatty K . Molecular forms of ruminant BMP15 and GDF9 and putative interactions with receptors. Reproduction. 2017; 154(4):521-534. DOI: 10.1530/REP-17-0188. View

19.

Otsuka F, Yao Z, Lee T, Yamamoto S, Erickson G, Shimasaki S . Bone morphogenetic protein-15. Identification of target cells and biological functions. J Biol Chem. 2000; 275(50):39523-8. DOI: 10.1074/jbc.M007428200. View

20.

Yan C, Wang P, DeMayo J, Demayo F, Elvin J, Carino C . Synergistic roles of bone morphogenetic protein 15 and growth differentiation factor 9 in ovarian function. Mol Endocrinol. 2001; 15(6):854-66. DOI: 10.1210/mend.15.6.0662. View